OLMA Olema Pharmaceuticals Inc
953
$9.06
$0.33
(3.78%)
| Watchers | 953 |
| 52-Wk Low | $5.02 |
| 52-Wk High | $17.79 |
| Market Cap | $506.76M |
| Volume | 625,146.00 |
| 52-Wk High | $17.79 |
| 52-Wk Low | $5.02 |
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032PR Newswire • 24 days ago
Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 PR Newswire VANCOUVER...
Share to Feed
The Goldman Sachs Group began coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA - Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm issued a...
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ( Olema or Olema Oncology , Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery...
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report) has earned an average recommendation of Buy from the seven brokerages that are currently covering the stock...
EP Wealth Advisors LLC increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Free Report) by 831.1% in the third quarter, according to its most recent Form 13F filing...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report)s share price shot up 11.9% during mid-day trading on Wednesday . The company traded as high as $13.59 and last traded at...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 29th, there was short interest...
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3...
This indicator may be signaling that OLMA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...